On August 10 2023, VACCITECH PLC ($NASDAQ:VACC) reported their FY2023 Q2 earnings results, which ended on June 30 2023. The quarter’s total revenue was USD 0.3 million, a 98.1% decrease compared to the same period in the prior year. Furthermore, the company experienced a net income of USD -23.8 million, significantly lower than the year-ago figure of USD 15.7 million.
VACCITECH PLC reported its fiscal year 2023 second quarter earnings results on Thursday, June 30, 2023. The company opened at $2.2 and closed at the same price, marking a 0.5% decrease from its last closing price of $2.2. Overall, VACCITECH PLC’s reported second quarter earnings results appear to be positive, showing strong revenue growth and steady cash flow. The company’s stock responded positively to the announcement and remains an attractive investment option for long-term investors looking for stable returns. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Vaccitech Plc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vaccitech Plc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vaccitech Plc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Vaccitech Plc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale conducted an analysis of VACCITECH PLC‘s wellbeing and found that it had an intermediate health score of 6/10 when it came to its cashflows and debt. This means that VACCITECH PLC has achieved moderate revenue or earnings growth, making it a “rhino” type of company. Based on this assessment, it is likely that VACCITECH PLC will be able to pay off its debt and fund future operations. Using the Star Chart, GoodWhale identified that VACCITECH PLC is strong in asset and growth but weak in dividend and profitability. As such, investors looking to invest in VACCITECH PLC should be confident in its growth prospects and be comfortable with the fact that the returns may take time to materialize. More…
Risk Rating Analysis
Star Chart Analysis
The company’s products are based on its Chimeric Antigen Receptor T-Cell platform technology. Its pipeline includes products for the treatment of human papillomavirus, non-small cell lung cancer, and melanoma. Vaccitech PLC is headquartered in Oxford, the United Kingdom. BerGenBio ASA is a clinical-stage biopharmaceutical company, which focuses on developing targeted therapies to treat cancer. The company’s products are based on its AXL kinase inhibitor program. Its pipeline includes products for the treatment of solid tumors and hematologic malignancies. BerGenBio ASA is headquartered in Oslo, Norway. VistaGen Therapeutics Inc is a biopharmaceutical company, which focuses on developing new therapies for central nervous system disorders. The company’s products are based on its Human Neural Stem Cell platform technology. Its pipeline includes products for the treatment of Parkinson’s disease, major depressive disorder, and Huntington’s disease. VistaGen Therapeutics Inc is headquartered in South San Francisco, California. CinCor Pharma Inc is a pharmaceutical company, which focuses on the development and commercialization of cardiovascular products. The company’s products include Isradipine, Omecamtiv Mecarbil, and Corsacor. CinCor Pharma Inc is headquartered in San Diego, California.
BerGenBio ASA is a clinical-stage biopharmaceutical company that focuses on developing novel, targeted therapeutics to treat serious unmet medical needs in cancer and other inflammatory diseases. The company’s market cap is 69.24M as of 2022 and has a Return on Equity of -71.18%. BerGenBio’s main product candidates are bemcentinib and encorafenib, which are currently in clinical trials for the treatment of various solid tumors and hematologic malignancies.
– VistaGen Therapeutics Inc ($NASDAQ:VTGN)
VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on developing and commercializing novel therapies to treat patients with central nervous system disorders. The company’s lead product candidate is AV-101, which is in Phase 2 clinical development for the treatment of major depressive disorder. The company has a market cap of $33.51 million and a return on equity of -67.47%.
CinCor Pharma Inc has a market cap of 1.23B as of 2022, a Return on Equity of 78.34%. The company focuses on the development and commercialization of pharmaceutical products for the treatment of cancer. The company’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer.
VACCITECH PLC reported their earnings for FY2023 Q2 and showed a significant decrease of 98.1% in total revenue to USD 0.3 million compared to the same period last year. Net income also took a dive to USD -23.8 million from 15.7 million the year prior. Given these results, investors may want to consider the viability of VACCITECH PLC as a potential investment. It is important to further analyze the financial status of the company to assess the risk associated with investing in it.
Additionally, investors should pay close attention to any news regarding the company’s prospects for the future.